Overview

Envarsus in Delayed Graft Function (E-DGF)

Status:
Recruiting

Trial end date:
2022-08-01

Target enrollment:

Participant gender:

Summary

Envarsus XR is an extended release tacrolimus designed to deliver tacrolimus more consistently, thus avoiding large fluctuations of tacrolimus trough levels with Envarsus XR compared to immediate release tacrolimus. It is expected that patients with DGF on Envarsus XR will have more stable tacrolimus levels and facilitate early recover from DGF compared to immediate release tacrolimus.

Phase:

Phase 4

Details

Lead Sponsor:

University of Wisconsin, Madison

Collaborator:

Veloxis Pharmaceuticals

Treatments:

Tacrolimus